The global Point Of Care (POC) Diagnostics Market is projected to grow from USD 47.8 billion in 2024 to USD 68.5 billion by 2030, at a CAGR of 6.1%. This growth is fueled by the increasing prevalence of infectious diseases, acute and chronic conditions, and improvements in healthcare facilities and infrastructure. The market is segmented by product, technology, application, end user, and geography.

By product, Glucose Monitoring is the dominant segment in 2024 due to the rising prevalence of diabetes. These portable, user-friendly devices are essential for managing blood glucose levels at home and in clinical settings. Infectious Disease Testing has seen significant growth, especially following global health emergencies like the COVID-19 pandemic. Quick diagnostic tests for diseases like influenza, HIV, and hepatitis are crucial for immediate treatment and preventing disease spread. The ability to move these diagnostic tools easily and their fast results make them indispensable for application in distant locations and during disease outbreaks.

By technology, Lateral Flow Assays lead the market in 2024 due to their simplicity and affordability, widely used in detecting infectious diseases, pregnancy, and substance abuse. Molecular Diagnostics is the fastest-growing technology segment due to its accuracy and sensitivity, critical for identifying infectious diseases in low-resource areas.

By application, Infectious Diseases is the largest segment in 2024 because of the urgent need for rapid diagnosis, particularly in areas lacking proper laboratory facilities. Diabetes applications continue to grow through the adoption of continuous glucose monitoring (CGM) systems and smart insulin delivery methods.

By end user, Hospitals & Clinics hold the highest market share in 2024 due to the high volume of patients requiring quick diagnostic results and skilled personnel. Home Care settings are expanding due to the increasing prevalence of chronic diseases and patient preference for managing health at home, supported by connected, user-friendly devices.

North America dominates the POC market due to its advanced healthcare infrastructure and widespread use of diagnostic tools. Europe holds a major market share through government initiatives promoting early diagnosis. The Asia-Pacific region is the fastest-growing due to increased healthcare investments and rising rates of infectious and chronic diseases.

Key players in the Point of Care Diagnostics Market include Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), QuidelOrtho Corporation (US), BD (US), Thermo Fisher Scientific Inc. (US), bioMérieux (France), BIOSYNEX SA (France), EKF Diagnostics Holdings plc (UK), Trinity Biotech (Ireland), Werfen (US), Nova Biomedical (US), SEKISUI Diagnostics (US), and Boditech Med Inc. (South Korea).

Abbott Laboratories holds a leadership position with products like the FreeStyle Libre system for glucose monitoring and the ID NOW platform for rapid molecular diagnostics. Roche Diagnostics offers the Accu-Chek line for diabetes care and the cobas Liat System for PCR-standard respiratory infection results. Siemens Healthineers provides critical care solutions like the epoc Blood Analysis System and CLINITEK urinalysis systems.

Recent developments include bioMérieux receiving FDA clearance for its BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel Mini, Roche acquiring LumiraDx's US Point of Care technology, and the FDA approving Roche's HPV self-testing kit. The WHO prequalified Cepheid's Xpert HIV-1 Qual XC, and the FDA cleared Abbott's i-STAT TBI cartridge. Thermo Fisher Scientific partnered with Project HOPE to extend HIV testing services in Sub-Saharan Africa.

The POC diagnostics market faces challenges such as unequal access in under-resourced areas and complex regulatory requirements. Opportunities include home-based testing, digital health platform integration, and investments in next-generation diagnostic technologies. The market's growth to USD 68.5 billion by 2030 presents significant opportunities for companies that adopt innovation and patient-centered solutions while maintaining regulatory compliance.